Topic: respiratory treatment
The respiratory franchise bore the brunt of the cuts at a time when some GSK staff were questioning the wisdom of investing in the field.
The appointments are part of Verona’s efforts to prepare for phase 3 development of ensifentrine in chronic obstructive pulmonary disease.
Symdeko doesn’t require specific blood-pressure monitoring, nor does it carry a warning about respiratory events, as Vertex's older treatment Orkambi does.
The biotech is now testing product batches to assess whether the formulation is to blame for the lackluster data.
The Big Pharma is paying €25 million to work with Ethris on respiratory diseases and bag the option to license the fruits of the collaboration.
Belgian biotech Galapagos has chalked up a positive phase 2a trial for its idiopathic pulmonary fibrosis (IPF) drug GLPG1690, saying it halted the relentless decline in lung function normally seen in patients.
Sunovion released some devastating news ahead of the holiday weekend, as the FDA threw a spanner into its plans to bring a new drug for chronic obstructive pulmonary disease (COPD) to market.
AstraZeneca has paid $45 million and committed to up to $2.1 billion in milestones to team with Pieris Pharmaceuticals.
Shares in U.K. biotech Synairgen were pummeled today as partner AstraZeneca revealed it was stopping development of its inhaled interferon beta therapy AZD9412.
Circassia CEO Steve Harris has defended the running of the company’s allergy trials, stating nothing could have been done better.